Phaseline

Companies › BioNTech Cell & Gene Therapies

BioNTech Cell & Gene Therapies: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CLDN6 CAR-T
CAR-T cell therapy targeting CLDN6
CLDN6Phase 1Solid TumorAug 2028
CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
RNA-based vaccine targeting CLDN6
CLDN6Phase 1Solid TumorAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04503278CLDN6 CAR-TPhase 1Solid TumorOncologyAug 2028
NCT04503278CLDN6 uRNA-LPX/CLDN6 modRNA-LPXPhase 1Solid TumorOncologyAug 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CLDN6 (2)

Companies with the same targets

Context Therapeutics BeOne Medicines NovaRock Biotherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.